Comparison of helical tomotherapy with multi-field intensity-modulated radiotherapy treatment plans using simultaneous integrated boost in high-risk prostate cancer

• Autorzy: Başaran Hamit , Karaca Sibel , Koca Timur , Gündoğdu Yasemin Örs

Identyfikatory

DOI

10.2478/pjmpe-2021-0017

• Języki publikacji: EN

Abstrakty

EN

Purpose: The aim of this study is to compare the dosimetric results of Helical Tomotherapy (HT) and Multi-field IMRT treatment plans using a Simultaneous Integrated Boost (SIB) technique in the treatment of High-Risk Prostate Cancer (HRPCa) with pelvic nodal radiation. Methods: Seventeen patients planned with HT and 7,8 and 9 fields IMRT were investigated. All plans were designed with the prescribed dose of 54.0 Gy to the PTVln while simultaneously delivering 74.0 Gy to the PTVPS in 30 fractions. Dosimetric data of PTV and OARs were compared. Results: HT gives a better CI and HI of PTVPS compared to multi-field IMRT plans. HT plans significantly improved target coverage (HT:0.95 vs multi-field IMRT: 0.52, 0.49 and 0.49 respectively, p < 0.001). Bladder mean dose(Gy) (HT: 45.6 vs multi-field IMRT: 53.6, 53.3 and 52.7 respectively, p = 0.004) and D66%(Gy) dose (HT: 35.3 vs multi-field IMRT: 46.7, 47.0 and 44.9 respectively, p = 0.006) were lower in HT. But multi-field IMRT plans significantly reduced the rectum volume receiving more than 75 Gy ; (HT V75% (%) 2.7 vs multi-field IMRT 0.8, 1.4 and 0.9 respectively, p = 0.008). HT provided better sparing of the right and left femoral head receiving a mean dose. The penile bulb and small bowel doses were the highest in HT compared with multi-field IMRT. Conclusions: HT achieved better dose distribution to target compared to multi-field IMRT. This study suggests HT as a reasonable option for the treatment of HRPCa patients.

Słowa kluczowe

EN

prostate cancer; tomotherapy; intensity modulated radiation therapy; simultaneous integrated boost

• Wydawca: Polskie Towarzystwo Fizyki Medycznej ; De Gruyter
• Czasopismo: Polish Journal of Medical Physics and Engineering
• Rocznik: 2021
• Tom: Vol. 27, Iss. 2
• Strony: 143--149
• Opis fizyczny: Bibliogr. 33 poz., rys., tab.

Twórcy

autor

Başaran Hamit

• Department of Radiation Oncology, Selçuk University Faculty of Medicine, Konya, Turkey
• Sağlık Bilimleri University, ErzurumRegional Training and Research Hospital, Department of Radiation Oncology, Erzurum, Turkey

autor

Karaca Sibel

• Sağlık Bilimleri University, ErzurumRegional Training and Research Hospital, Department of Radiation Oncology, Erzurum, Turkey
• Department of Radiation Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey

autor

Koca Timur

• Sağlık Bilimleri University, ErzurumRegional Training and Research Hospital, Department of Radiation Oncology, Erzurum, Turkey
• Department of Radiation Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey

autor

Gündoğdu Yasemin Örs

• Sağlık Bilimleri University, ErzurumRegional Training and Research Hospital, Department of Radiation Oncology, Erzurum, Turkey

Bibliografia

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/ 10.3322/caac.21590
• 2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancerstatistics 2018: GLOBOCAN estimates of incidence and mortality World wide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020;70(4):313.
• 3. Kuban DA, Tucker SL, Dong L, et al. Long-termresults of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74. https://doi.org/10.1016/j.ijrobp.2007.06.054
• 4. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464-73. https://doi.org/ 10.1016/S1470-2045(14)70040-3
• 5. Cilla S, Deodato F, Digesù C, Macchia G, Picardi V, Ferro M, Sallustio G, De Spirito M, Piermattei A, Morganti AG. Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases. Med Dosim. 2014 Spring;39(1):108-16. https://doi.org/ 10.1016/j.meddos.2013.11.001.Epub 2013 Dec 15. PMID: 24342167.
• 6. Saracino B, Petrongari MG, Marzi S, et al. Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control. Cancer Med. 2014;3(5):1313-1321. https://doi.org/10.1002/cam4.278
• 7. Pacelli R, Caroprese M, Palma G, et al. Technologicalevolution of radiationtreatment: Implications for clinical applications. Semin Oncol. 2019;46(3):193-201. https://doi.org/10.1053/j.seminoncol.2019.07.004
• 8. Cuccia F, Mazzola R, Arcangeli S, et al. Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori. 2019;105(6):516‐523. https://doi.org/10.1177/0300891619867846
• 9. Morikawa LK, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011;80(1):6-16. https://doi.org/10.1016/j.ijrobp.2010.11.074
• 10. Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reachconsensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383-7. https://doi.org/10.1016/j.ijrobp.2008.08.002
• 11. Liang J, Wu Q, Yan D. The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(3):935-43. https://doi.org/10.1016/j.ijrobp.2008.10.019
• 12. Ramiandrisoa F, Duvergé L, Castelli J, et al. Détermination des marges du volume cible anatomoclinique au volume cible prévisionnel pour la radiothérapie du cancer prostatique [Clinical to planning target volume margins in prostate cancer radiotherapy]. Cancer Radiother. 2016 Oct;20(6-7):629-39. French. https://doi.org/10.1016/j.canrad.2016.07.095
• 13. Piotrowski T, Kaczmarek K, Bajon T, et al. Evaluation of image-guidance strategies for prostate cancer. Technol Cancer Res Treat. 2014;13(6):583-91. https://doi.org/10.7785/tcrtexpress.2013.600258
• 14. Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiationtherapy: A RadiationTherapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012;83:e353-e362. https://doi.org/10.1016/j.ijrobp.2012.01.023
• 15. International Commission on Radiation Units and Measurements Report 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 2010;10(1). https://doi.org/10.1093/jicru/ndq002
• 16. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury [published correction appears in Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1185]. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S123-S129. https://doi.org/10.1016/j.ijrobp.2009.03.078
• 17. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arctherapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D conformal RT for treatment of prostate cancer. Radiother Oncol 2009; 93:226-233. https://doi.org/10.1016/j.radonc.2009.08.011
• 18. Shaw E, Kline R, Gillin M, et al. Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys. 1993;27:1231-1239. https://doi.org/10.1016/0360-3016(93)90548-a
• 19. Feuvret L, Noël G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys. 2006;64(2):333-42. https://doi.org/10.1016/j.ijrobp.2005.09.028
• 20. Kataria T, Sharma K, Subramani V, et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys. 2012;37(4):207-213. https://doi.org/10.4103/0971-6203.103606
• 21. Ning ZH, Mu JM, Jin JX, et al. Single arc volumetric-modulated arc therapy is sufficient for nasopharyngeal carcinoma: a dosimetric comparison with dual arc VMAT and dynamic MLC and step-and-shoot intensity-modulated radiotherapy. Radiat Oncol. 2013;8:237. https://doi.org/10.1186/1748-717X-8-237
• 22. Skórska M, Piotrowski T. Optimization of treatment planning parameters used in tomotherapy for prostate cancer patients. Phys Med. 2013;29(3):273-85. https://doi.org/ 10.1016/j.ejmp.2012.03.007
• 23. Cao D, Holmes TW, Afghan MK, Shepard DM. Comparison of plan quality provided by intensity-modulated arc therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;69(1):240-50. https://doi.org/10.1016/j.ijrobp.2007.04.073
• 24. Tsai CL, Wu JK, Chao HL, et al. Treatment and dosimetric advantages between VMAT, IMRT, and helical tomotherapy in prostate cancer. Med Dosim. 2011;36(3):264-71. https://doi.org/10.1016/j.meddos.2010.05.001
• 25. Rong Y, Tang G, Welsh JS, et al. Helical tomotherapy versus single-arc intensity-modulated arctherapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys. 2011;81(1):284-96. https://doi.org/10.1016/j.ijrobp.2010.10.059
• 26. Ishii K, Ogino R, Okada W, et al. A dosimetric comparison of RapidArc and IMRT with hypofractionated simultaneous integrated boost to the prostate for treatment of prostate cancer. Br J Radiol. 2013;86(1030):20130199. https://doi.org/10.1259/bjr.20130199
• 27. Davidson MT, Blake SJ, Batchelar DL, et al. Assessingthe role of volumetricmodulatedarctherapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1550-8. https://doi.org/10.1016/j.ijrobp.2010.10.024
• 28. Pasquier D, Cavillon F, Lacornerie T, et al. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(2):549‐554. https://doi.org/10.1016/j.ijrobp.2012.03.046
• 29. Servagi-Vernat S, Giraud P, Fenoglietto P, et al. Apport de la RCMI rotationnelle et de la tomothérapiehélicoïdaledans les cancers pelviens : étudedosimétrique prospective sur 51 patients [Impact of dynamic IMRT and tomotherapy in pelvic cancers: a prospective dosimetric study with 51 patients]. Cancer Radiother. 2014;18(2):111‐118. https://doi.org/10.1016/j.canrad.2013.12.008
• 30. Abu-Gheida I, Reddy CA, Kotecha R, et al. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):325‐333. https://doi.org/10.1016/j.ijrobp.2019.01.091
• 31. Widesott L, Pierelli A, Fiorino C, et al. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys. 2011;80(5):1589‐1600. https://doi.org/10.1016/j.ijrobp. 2010.10.005
• 32. Barelkowski T, Wust P, Kaul D, et al. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. Strahlenther Onkol. 2020;196(3):229‐242. https://doi.org/10.1007/s00066-019-01562-2
• 33. Beck M, Wust P, Barelkowski T, et al. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. Radiat Oncol. 2017;12(1):125. https://doi.org/10.1186/s13014-017-0862-4

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2021).